Dataset Information

Cyclin D1 Transgenic Mice with Bim-deficient B-cells

ABSTRACT: Expression analysis from a genetically engineered mouse model of mantle cell lymphoma (MCL) Gene expression was measured in fourteen mice that overexpress cyclin D1 and delete Bim in their B cells and that were stimulated with sheep red blood cells (SRBC) and irradiation (I), pristane (P) or only SRBC weekly (A). Mice that developed disease based on histopathologic criteria were compared to ones that did not. An additional seven stimulated mice that only overexpressed cyclin D1 were used to estimate the data set variance.

OTHER RELATED OMICS DATASETS IN: PRJNA227163

ORGANISM(S): Mus Musculus

SUBMITTER: Steven H Kleinstein Hailong Meng Loren D Walensky Samuel G Katz

PROVIDER: E-GEOD-52214 | ArrayExpress | 2014-02-05

SECONDARY ACCESSION(S): GSE52214PRJNA227163

REPOSITORIES: GEO, ArrayExpress

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	E-GEOD-52214.additional.1.zip	Other
	E-GEOD-52214.idf.txt	Idf
	E-GEOD-52214.processed.1.zip	Processed
	E-GEOD-52214.sdrf.txt	Txt

Items per page:

1 - 4 of 4

Publications

Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.

Katz Samuel G SG Labelle James L JL Meng Hailong H Valeriano Regina P RP Fisher Jill K JK Sun Heather H Rodig Scott J SJ Kleinstein Steven H SH Walensky Loren D LD

Blood 20131218 6

Mantle cell lymphoma (MCL) is a highly aggressive B-cell lymphoma resistant to conventional chemotherapy. Although defined by the characteristic t(11;14) translocation, MCL has not been recapitulated in transgenic mouse models of cyclin D1 overexpression alone. Indeed, several genetic aberrations have been identified in MCL that may contribute to its pathogenesis and chemoresistance. Of particular interest is the frequent biallelic deletion of the proapoptotic BCL-2 family protein BIM. BIM exert ...[more]

PMID: 24352880

Similar Datasets

Project description:Red blood cell (RBC) transfusion exposes recipients to hundreds of unmatched minor RBC antigens. This exposure can lead to production of alloantibodies that promote clinically significant hemolytic events. Multiple studies have reported an increased frequency of RBC alloimmunization in patients with autoimmunity. However, cellular and molecular mechanisms that underlie autoimmunity-induced alloimmunization have not been reported. Patients with systemic lupus erythematosus (SLE) have a high frequency of alloimmunization and express a type 1 interferon (IFN?/?) gene signature. Thus, we utilized the pristane-induced lupus mouse model to test the hypothesis that inflammation in lupus promotes RBC alloimmunization, and to examine the potential role of IFN?/?. Intraperitoneal injection of pristane, a hydrocarbon oil, led to autoantibody production, glomerulonephritis, and pulmonary hemorrhage in wild type (WT) mice. Pristane treatment significantly induced serum IFN? and expression of multiple interferon-stimulated genes (ISGs) in peripheral blood and peritoneal fluid cells, including inflammatory macrophages. Following transfusion with allogeneic RBCs expressing the KEL glycoprotein, pristane-treated WT mice produced significantly elevated levels of anti-KEL IgM and anti-KEL IgG, compared to untreated mice. Pristane induced comparable levels of inflammatory cells and cytokines in mice lacking the IFN?/? receptor (IFNAR1-/-) or the IFN?/?-inducing transcriptions factors (IRF3/7-/-), compared to WT mice. However, pristane-treated IFNAR1-/- and IRF3/7-/- mice failed to produce ISGs and produced significantly lower levels of transfusion-induced anti-KEL IgG, compared to WT mice. Thus, pristane induction of a lupus-like phenotype promoted alloimmunization to the KEL RBC antigen in an IFN?/?-dependent manner. To our knowledge, this is the first examination of molecular mechanisms contributing to RBC alloimmunization in a model of autoimmunity. These results warrant further investigation of the role of IFN?/? in alloimmunization to other RBC antigens and the contribution of the IFN?/? gene signature to the elevated frequency of alloimmunization in patients with SLE.